The recent approval of 4 agents for the treatment of patients with metastatic HER2-positive breast cancer has led to expanded recommendations in the NCCN Guidelines for treatment of this disease. For triple-negative disease, immunotherapy continues to gain traction in this challenging subtype, both in the preoperative and metastatic settings, though not yet as adjuvant treatment. Sacituzumab govitecan is another new agent with strong utility in triple-negative disease, and PARP inhibitors are recommended options in BRCA-mutated disease.
Disclosures: Dr. Telli has disclosed serving as a scientific advisor for and receiving consulting fees from AbbVie, Inc., Celgene Corporation, Immunomedics, Inc., Merck & Co., Inc., Lilly Oncology, Natera, and Pfizer Inc. Dr. Gradishar has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, MacroGenics, Inc., Pfizer Inc., Roche Laboratories, Inc./Genentech, Inc., and Seattle Genetics, Inc.